Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: The study was undertaken to define the relationship between tumor response and carboplatin area under the curve (AUC) in patients with ovarian cancer; to study the relationship between carboplatin AUC and myelosuppression in the same population; to establish the true impact of carboplatin AUC, prior therapy, and pretreatment platelet and WBC counts on toxicity; and to define an optimal carboplatin exposure for treating patients with ovarian cancer. METHODS: With the equation AUC = dose/(glomerular filtration rate [GFR]+25), carboplatin AUC (course 1) was calculated for 1,028 patients (450 previously untreated) who received single-agent carboplatin (40 to 1,000 mg/m2) for advanced ovarian cancer. GFR was measured (chromium-51-edathamil [51Cr-EDTA] or creatinine clearance) in all patients. RESULTS: Regression analysis showed that carboplatin AUC, prior treatment, and Eastern Cooperative Oncology Group grade performance status (PS) are predictors of tumor response, thrombocytopenia, and leukopenia. Pretreatment platelet and WBC counts are additional predictors of thrombocytopenia and leukopenia, respectively. Although the likelihood of tumor response increased with increasing carboplatin AUC, this relationship was nonlinear. In all patient subsets, the likelihood of complete response (CR) or overall response did not increase significantly above a carboplatin AUC of 5 to 7 mg/mL x minutes. At any given carboplatin AUC, thrombocytopenia occurred more frequently than leukopenia, although both approached 100% as carboplatin AUC increased. Both thrombocytopenia and leukopenia were more frequent in pretreated than in untreated patients regardless of pretreatment count. At any carboplatin AUC, the influence of PS on likelihood of response and toxicity was profound. CONCLUSION: Carboplatin dosing by AUC will lead to more predictable toxicity, and increasing carboplatin AUC above 5 to 7 mg/mL x minutes does not improve the likelihood of response but does increase myelotoxicity. Therefore, careful evaluation of high-dose carboplatin therapy in a prospective, randomized trial is needed before such treatment becomes accepted practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Self-citationBiopharmaceutics and clinical pharmacokinetics
(1991) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(91)90260-d · Cited by 691
A program package for simulation and parameter estimation in pharmacokinetic systems
D'argenio, D. Z., & Schumitzky, A. (1979) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(79)90025-4 · Cited by 471
Grochow, L. B., Jones, R. J., Brundrett, R. B., Braine, H. G., Chen, T.-L., Saral, R., Santos, G. W., & Colvin, O. M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694339 · Cited by 404
Wagner, J. G. (1968) · Journal of Theoretical Biology · doi:10.1016/0022-5193(68)90188-4 · Cited by 305
Ovarian trials at the Royal Marsden
Wiltshaw, E. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90020-9 · Cited by 113
Self-citationEgorin, M. J., Echo, D. A. V., Whitacre, M. Y., Forrest, A., Sigman, L. M., Engisch, K. L., & Aisner, J. (1986) · PubMed · Cited by 60
Self-citationRegression with an ordered categorical response
Hastie, T. J., Botha, J. L., & Schnitzler, C. M. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080703 · Cited by 54
Cited by
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Self-citationToxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Eisenkop, S. M., Friedman, R. L., & Wang, H.-J. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.4955 · Cited by 507
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Gurney, H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2590 · Cited by 361
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
KINTZEL, P. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90010-1 · Cited by 357
Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., Geller, N. L., Fair, W. R., Herr, H., & Sogani, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.598 · Cited by 354
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
Lokich, J., & Anderson, N. (1998) · Annals of Oncology · doi:10.1023/a:1008215213739 · Cited by 304
Cannistra, S. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292108 · Cited by 291
Dressman, H. K., Berchuck, A., Chan, G., Zhai, J., Bild, A., Sayer, R., Cragun, J., Clarke, J., Whitaker, R. S., Li, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3743 · Cited by 282
RetractedReview of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
Paci, A., Veal, G., Bardin, C., Levêque, D., Widmer, N., Beijnen, J., Astier, A., & Chatelut, E. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.014 · Cited by 260
Evolution of platinum resistance in high-grade serous ovarian cancer
Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213
Metadata
- Authors
- Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-04
- Volume
- 10
- Issue
- 4
- Pages
- 520-528
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2147869809
- Cited by
- 381
- References
- 9
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.